<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Morgado, P.</style></author><author><style face="normal" font="default" size="100%">Marques, F.</style></author><author><style face="normal" font="default" size="100%">Ribeiro, B.</style></author><author><style face="normal" font="default" size="100%">Leite-Almeida, H</style></author><author><style face="normal" font="default" size="100%">Pêgo, J M</style></author><author><style face="normal" font="default" size="100%">Rodrigues, A. J.</style></author><author><style face="normal" font="default" size="100%">Dalla, C</style></author><author><style face="normal" font="default" size="100%">Kokras, N</style></author><author><style face="normal" font="default" size="100%">Sousa, N.</style></author><author><style face="normal" font="default" size="100%">Cerqueira, J. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Stress induced risk-aversion is reverted by D2/D3 agonist in the rat</style></title><secondary-title><style face="normal" font="default" size="100%">Eur Neuropsychopharmacol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Risk-Taking</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Chronic Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Decision Making/drug effects/*physiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Decision-making</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Dopamine</style></keyword><keyword><style  face="normal" font="default" size="100%">Dopamine Agonists/pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Dopamine/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Insula</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Orbitofrontal</style></keyword><keyword><style  face="normal" font="default" size="100%">Prefrontal Cortex/drug effects/*metabolism/pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Pyramidal Cells/drug effects/metabolism/pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Quinpirole</style></keyword><keyword><style  face="normal" font="default" size="100%">Quinpirole/pharmacology</style></keyword><keyword><style  face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptors, Dopamine D2/agonists/*metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptors, Dopamine D3/agonists/*metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style  face="normal" font="default" size="100%">stress</style></keyword><keyword><style  face="normal" font="default" size="100%">Stress, Psychological/drug therapy/*metabolism/pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">uncertainty</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Oct</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">10</style></number><edition><style face="normal" font="default" size="100%">20150720</style></edition><volume><style face="normal" font="default" size="100%">25</style></volume><pages><style face="normal" font="default" size="100%">1744-52</style></pages><isbn><style face="normal" font="default" size="100%">0924-977x</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Stress exposure triggers cognitive and behavioral impairments that influence decision-making processes. Decisions under a context of uncertainty require complex reward-prediction processes that are known to be mediated by the mesocorticolimbic dopamine (DA) system in brain areas sensitive to the deleterious effects of chronic stress, in particular the orbitofrontal cortex (OFC). Using a decision-making task, we show that chronic stress biases risk-based decision-making to safer behaviors. This decision-making pattern is associated with an increased activation of the lateral part of the OFC and with morphological changes in pyramidal neurons specifically recruited by this task. Additionally, stress exposure induces a hypodopaminergic status accompanied by increased mRNA levels of the dopamine receptor type 2 (Drd2) in the OFC; importantly, treatment with a D2/D3 agonist quinpirole reverts the shift to safer behaviors induced by stress on risky decision-making. These results suggest that the brain mechanisms related to risk-based decision-making are altered after chronic stress, but can be modulated by manipulation of dopaminergic transmission.</style></abstract><accession-num><style face="normal" font="default" size="100%">26233608</style></accession-num><notes><style face="normal" font="default" size="100%">10.1016/j.euroneuro.2015.07.003</style></notes><auth-address><style face="normal" font="default" size="100%">Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS-3Bs PT Government Associate Laboratory, Braga, Guimarães, Portugal.Department of Pharmacology, Medical School, University of Athens, Athens, Greece.Department of Pharmacology, Medical School, University of Athens, Athens, Greece; First Department of Psychiatry, Eginition Hospital, Medical School, University of Athens, Athens, Greece.Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS-3Bs PT Government Associate Laboratory, Braga, Guimarães, Portugal. Electronic address: jcerqueira@ecsaude.uminho.pt.</style></auth-address><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record></records></xml>